$2.12 Pre Market 18 Feb 2026: MBOT Microbot Medical Inc NASDAQ – 91% upside

MBOT stock trades at $2.12 pre market on 18 Feb 2026, down 2.30% from the prior close. Microbot Medical Inc. (MBOT) on the NASDAQ shows a market cap of $96,609,316.00 and rising short-term momentum as investors await a key earnings update on 25 Feb 2026. We examine valuation, technicals, and model forecasts to frame an AI-driven view of risk and potential upside for MBOT stock.

MBOT stock: Price snapshot and intraday data

Current price: $2.12 USD on NASDAQ with volume 1,815,387 and average volume 2,279,458.00. Day range is $2.03–$2.22, year range $1.25–$4.67. EPS is -0.45 and reported PE is -4.71, reflecting negative earnings but meaningful cash per share of $1.67.

These raw figures connect directly to short-term liquidity and market reaction. Low float and higher-than-average daily turnover have driven a 5‑day change of +7.07%, showing short-term trader interest in MBOT stock.

Drivers: clinical progress, partnerships and MBOT news

Microbot Medical focuses on robotic endoluminal devices and lists partnerships including a collaboration with Stryker. Recent headlines and chart coverage from Barron’s and MarketBeat keep MBOT stock in play for traders. See latest coverage at Barron’s MBOT research and MarketBeat MBOT news.

Clinical milestones and regulatory updates remain the primary catalysts that can compress uncertainty into price moves. Investors should track the upcoming earnings announcement on 25 Feb 2026 and any progress updates on ViRob, TipCAT and other micro-robotic programs.

Financials and valuation for MBOT stock

Microbot shows strong liquidity metrics: current ratio 27.53 and cash per share $1.67, but negative operating cash flows per share of -0.23. Book value per share stands near $1.63 and price-to-book is ~1.34, implying the market values growth optionality above current book assets.

Revenue is minimal at present; the company remains pre-revenue in commercial scale. Investors should weigh a PB ratio of 1.34 and negative ROE -37.06% against R&D runway and partnership potential when assessing MBOT stock valuation.

Technical view, momentum and Meyka AI grade

Technical indicators show mixed short-term strength: RSI 57.25, MACD histogram slightly positive, and ADX 27.15 signaling a developing trend. Bollinger bands sit at Upper $2.21 / Middle $1.93 / Lower $1.64, which frames near-term resistance and support for MBOT stock.

Meyka AI rates MBOT with a score out of 100: 70.51 / Grade B+ / Suggestion: BUY. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, analyst consensus and forecast models. Grades are informative but not guarantees and do not constitute financial advice.

Risks, catalysts and trading strategy for MBOT stock

Primary risks are clinical trial setbacks, dilution from further financing, and continued negative earnings. Dilution is visible in recent weighted average shares growth of 53.38% year over year. Catalyst events include the 25 Feb 2026 earnings announcement and any regulatory feedback on pipeline devices.

For traders using an AI stocks strategy, consider defined-risk positions sized to absorb volatility. Watch volume spikes around news and the 50‑day average price $2.09 as a short-term trend reference for MBOT stock.

Final Thoughts

Key takeaways for MBOT stock: price sits at $2.12 USD pre market on 18 Feb 2026 with meaningful short-term momentum and a market cap of $96,609,316.00. Financials show strong cash per share $1.67 but persistent negative earnings and cash flow. Meyka AI’s forecast model projects a yearly target of $4.06 USD, implying an upside of 91.26% versus today’s price. That projection uses historical patterns, sector signals, and analyst consensus and should be viewed as a model-based scenario, not a guarantee. Traders should monitor the 25 Feb 2026 earnings release, clinical updates, and any financing moves. For an AI-driven perspective and real-time data on MBOT stock, see our platform at MBOT on Meyka. Meyka AI is an AI-powered market analysis platform providing model forecasts and grades to help frame risk-reward in small-cap healthcare names.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.